以色列特拉维夫 / 北卡罗来纳州罗利，2017年11月13日 RedHill Biopharma Ltd.（纳斯达克：RDHL）（特拉维夫股票交易所：RDHL）（“RedHill”或“公司”）是一家专业生物制药公司，主要致力于专有胃肠疾病、炎症性疾病和癌症药物的后期临床开发和商业化。本公司今天披露了截至2017年9月30日的第三季度财报。
RedHill继续保持零债务，截至2017年第三季度末持有3960万美元现金。
此外，本公司定于今日（2017年11月13日）完成美国存托凭证承销公开发行，扣除承销折扣、佣金费和其他发行费用之后，共募集净所得约2060万美元。本次公开发行受惯常合同条款约束。
2017年第三季度，在美国推销三款胃肠专业产品取得约150万美元净收入，其中Donnatal®和EnteraGam® 在今年6月份推出，49.3毫克埃索美拉唑锶迟释胶囊在9月中旬推出。
2018年季度烧钱率预计将下降，营收将保持增长。
本公司更加重视合作，以及RedHill 精选开发项目在美国的联合推广。
精选近期及潜在里程碑：
“2017年第三季度是Donnatal®和EnteraGam®开始推广之后的第一个完整季度，实现了150万美元净收入。9月中旬49.3毫克埃索美拉唑锶迟释胶囊开始推广工作，我们预计之后净营收将继续增长，”RedHill首席财务官Micha Ben Chorin说道，“我们预计2018年季度烧钱率将下降，营收将继续增长。截至第三季度末公司现金结余3960万美元，此外，2017年11月美国存托凭证承销公开发行募集约2060万美元净所得资金。这些资金将使公司能够在2018年实现重要里程碑，包括RHB-104在2018年中发布治疗克罗恩病的三期试验结果，以及TALICIA™ (RHB-105) 在2018年下半年发布治疗幽门杆菌感染的验证性三期试验结果。”
电话会议和网络直播信息：
本公司已于周一（2017年11月13日）召开电话会议，回顾财务结果和业务亮点。可登陆公司网站http://ir.redhillbio.com/events.cfm重听电话会议内容，重听有效期30天。
RedHill Biopharma Ltd介绍：
RedHill Biopharma Ltd(纳斯达克：RDHL)(特拉维夫股票交易所：RDHL)是一家专业生物医药公司，主要专注于肠胃疾病和炎症性疾病以及癌症方面后期临床试验阶段的专有药物的开发和商业化。RedHill在美国推广三款胃肠产品，其临床阶段的产品管线包括胃肠适应症、胰腺癌和急性偏头痛药物：Donnatal® – 肠易激综合征和急性小肠结肠炎口服处方辅助药物；49.3毫克埃索美拉唑锶迟释胶囊 – 成人胃食管反流疾病和其他胃肠疾病的质子泵抑制剂；以及EnteraGam® – 医生监督下慢性腹泻和稀便饮食管理的医疗食品。RedHill目前处于临床阶段的产品管线包括：(i)TALICIA™(RHB—105)—幽门螺杆菌感染口服混合药，首项三期试验获得成功，正在进行验证性三期试验；(ii)RHB—104—克罗恩病口服混合药，正在进行首项三期试验，已经完成治疗多发性硬化症的概念验证IIa期试验幷计划进行治疗非结核性分枝杆菌感染的关键性三期试验；(iii)BEKINDA®(RHB—102)—日服一次的昂丹司琼口服片剂，急性肠胃炎和慢性胃炎三期试验取得成功结果，腹泻型肠易激综合征二期试验取得成功结果；(iv)RHB—106—肠道准备药物胶囊，已经授权给Salix Pharmaceuticals Ltd.；(v)YELIVA® (ABC294640)—二期阶段的口服SK2选择性抑制剂，是首创新药，靶向为多种肿瘤、炎症性和胃肠道适应症；(vi)MESUPRON—处于二期试验阶段的口服蛋白酶抑制剂，是首创新药，靶向为胰腺癌和炎症性胃肠疾病；(vii)RIZAPORT® (RHB—103)—利扎曲坦口服薄膜制剂，治疗急性偏头痛，已经向美国食品药品监督管理局重新提交新药申请，并已通过欧洲分散审批程序在两个欧盟国家获得上市许可。
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully market Donnatal® and EnteraGam®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.
注：该新闻稿的唯一官方版本是本公司发布的英文原版稿件。本摘要和翻译版本仅供方便阅读之目的。
| 公司联络人：
Adi Frish 业务发展和许可高级副总裁 RedHill Biopharma +972-54-6543-112 |
投资者关系联络人（美国）：
Marcy Nanus 高级副总裁 The Trout Group +1-646-378-2927 |
